BRIEF-Inovio Says 85% Of Glioblastoma Patients Treated With INO-5401 Combined with Libtayo Alive for at least 12 Months

May 14 (Reuters) - Inovio Pharmaceuticals Inc:

* INOVIO’S INO-5401 IN COMBINATION WITH PD-1 INHIBITOR LIBTAYO® (CEMIPLIMAB) DEMONSTRATES 85% OF NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS ARE ALIVE 12 MONTHS FOLLOWING TREATMENT Source text for Eikon: Further company coverage: